Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)
China · Delayed Price · Currency is CNY 8.92
-0.13 (-1.44%)
May 20, 2026, 2:05 PM CST
SHE:300016 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,234 | 1,196 | 973.49 | 884.3 | 761.45 | 856.85 |
Other Revenue | 9 | 9 | 10.07 | 6.42 | 4.43 | 3.06 |
| 1,243 | 1,205 | 983.55 | 890.72 | 765.88 | 859.91 | |
Revenue Growth (YoY) | 17.40% | 22.54% | 10.42% | 16.30% | -10.93% | 3.94% |
Cost of Revenue | 679.46 | 662.31 | 524.59 | 485.37 | 365.47 | 327.99 |
Gross Profit | 563.51 | 542.96 | 458.97 | 405.35 | 400.41 | 531.92 |
Selling, General & Admin | 360.54 | 354.15 | 332.21 | 298.78 | 296.25 | 363.6 |
Research & Development | 87.44 | 93.39 | 69.24 | 122.33 | 99.01 | 47.23 |
Other Operating Expenses | 2.26 | 3 | 5.22 | 5.6 | 11.16 | -5 |
Operating Expenses | 454.77 | 455.1 | 405.73 | 430.35 | 405.53 | 404.37 |
Operating Income | 108.73 | 87.86 | 53.24 | -25 | -5.12 | 127.55 |
Interest Expense | -28.04 | -39.78 | -58.01 | -53.14 | -47.64 | -44.19 |
Interest & Investment Income | 15.34 | 12.36 | 12.73 | 17.81 | 8.48 | 26.32 |
Currency Exchange Gain (Loss) | -3.03 | -3.03 | 1.18 | -2.76 | -1.14 | 5.31 |
Other Non Operating Income (Expenses) | -2.69 | -0 | -0.74 | -0.38 | -1.79 | -1.84 |
EBT Excluding Unusual Items | 90.31 | 57.41 | 8.4 | -63.47 | -47.21 | 113.15 |
Impairment of Goodwill | - | - | - | -31.82 | - | - |
Gain (Loss) on Sale of Investments | 56.19 | 53.44 | -11.95 | -13.96 | 20.54 | 13.9 |
Gain (Loss) on Sale of Assets | 0.03 | -1.23 | 0.12 | 0.89 | 0.1 | 0.13 |
Asset Writedown | 1.71 | -0.64 | -1.14 | -1.24 | -0.36 | -0.76 |
Other Unusual Items | -0.66 | -0.46 | 3.78 | 8.43 | 12.17 | -4.06 |
Pretax Income | 147.59 | 108.51 | -0.78 | -101.15 | -14.76 | 122.36 |
Income Tax Expense | 26.09 | 19.87 | -1.05 | -17.95 | -10.21 | 12.06 |
Earnings From Continuing Operations | 121.5 | 88.65 | 0.27 | -83.2 | -4.55 | 110.29 |
Minority Interest in Earnings | 1.67 | 4.09 | 13.38 | 11.44 | 15.83 | 15.22 |
Net Income | 123.17 | 92.73 | 13.65 | -71.76 | 11.28 | 125.51 |
Net Income to Common | 123.17 | 92.73 | 13.65 | -71.76 | 11.28 | 125.51 |
Net Income Growth | 639.15% | 579.29% | - | - | -91.01% | -28.16% |
Shares Outstanding (Basic) | 535 | 515 | 455 | 478 | 564 | 483 |
Shares Outstanding (Diluted) | 535 | 515 | 455 | 478 | 564 | 483 |
Shares Change (YoY) | 17.86% | 13.21% | -4.88% | -15.21% | 16.87% | -0.52% |
EPS (Basic) | 0.23 | 0.18 | 0.03 | -0.15 | 0.02 | 0.26 |
EPS (Diluted) | 0.23 | 0.18 | 0.03 | -0.15 | 0.02 | 0.26 |
EPS Growth | 527.17% | 500.00% | - | - | -92.31% | -27.78% |
Free Cash Flow | 3.23 | -62.3 | 61.63 | -86.15 | 25.03 | -39.03 |
Free Cash Flow Per Share | 0.01 | -0.12 | 0.14 | -0.18 | 0.04 | -0.08 |
Dividend Per Share | - | - | 0.050 | - | 0.070 | 0.070 |
Dividend Growth | - | - | - | - | - | 16.67% |
Gross Margin | 45.34% | 45.05% | 46.66% | 45.51% | 52.28% | 61.86% |
Operating Margin | 8.75% | 7.29% | 5.41% | -2.81% | -0.67% | 14.83% |
Profit Margin | 9.91% | 7.69% | 1.39% | -8.06% | 1.47% | 14.60% |
Free Cash Flow Margin | 0.26% | -5.17% | 6.27% | -9.67% | 3.27% | -4.54% |
EBITDA | 204.54 | 182.75 | 144.44 | 56.28 | 69.81 | 190.24 |
EBITDA Margin | 16.46% | 15.16% | 14.69% | 6.32% | 9.11% | 22.12% |
D&A For EBITDA | 95.81 | 94.89 | 91.21 | 81.28 | 74.93 | 62.7 |
EBIT | 108.73 | 87.86 | 53.24 | -25 | -5.12 | 127.55 |
EBIT Margin | 8.75% | 7.29% | 5.41% | -2.81% | -0.67% | 14.83% |
Effective Tax Rate | 17.68% | 18.31% | - | - | - | 9.86% |
Revenue as Reported | 1,243 | 1,205 | 983.55 | 890.72 | 765.88 | 859.91 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.